» Articles » PMID: 37090048

Detection of Anti-ganglioside Antibodies in Guillain-Barré Syndrome

Overview
Journal Ann Transl Med
Date 2023 Apr 24
PMID 37090048
Authors
Affiliations
Soon will be listed here.
Abstract

Gangliosides are a class of glycosphingolipid molecules that are highly enriched in cellular membranes of the nervous system. The gangliosides associated with autoimmune diseases of the nervous system are mainly GM1, GD1a, GalNAc-GD1a, GM1b, GD3, CD1b, GT1a, and GQ1b. Multiple antibodies recognizing gangliosides are associated with some acute or chronic peripheral neuropathies, especially Guillain-Barré syndrome (GBS) and its clinical variants. Antibodies binding to gangliosides can activate complement system and recruit macrophages on the axolemma at the nodes of Ranvier of motor fibers, which are found in the course of GBS, causing axonal degeneration and reversible conduction block or conduction failure. Testing of anti-gangliosides autoantibodies is helpful for diagnosis of autoimmune peripheral neuropathies or support the diagnosis of the subtypes. These anti-gangliosides antibodies are usually detected by several qualitative or quantitative methods, particularly enzyme-linked immunosorbent assay (ELISA) and immunodot assays, which have been commercialized or established in-house worldwide. Herein, we introduce the methods and clinical applications of these assays in the diagnosis of autoimmune peripheral neuropathies. Anti-gangliosides antibodies are diagnostic markers of GBS subtypes. We use GBS as an example to explain the role of anti-gangliosides antibodies in the pathogenesis and diagnostic classification of neuropathies.

Citing Articles

Unique Clinical and Psychiatric Challenges in Elderly Patients With Guillain-Barré Syndrome: A Case Series.

Obara K Cureus. 2024; 16(9):e69478.

PMID: 39416575 PMC: 11480000. DOI: 10.7759/cureus.69478.


Neurolymphomatosis mimicking a Guillain-Barré syndrome triggered by COVID-19 vaccination.

Colombo D, Falasca L, Monardo F, DAmbrosio M, Di Napoli A, Salerno A Neuropathology. 2024; 45(1):76-82.

PMID: 39311044 PMC: 11787998. DOI: 10.1111/neup.13003.


Case report: Bilateral facial palsy with paresthesias and positive anti-GT1a antibodies.

Xu X, Wang Z, Su C, Cong L, Zheng D Front Immunol. 2024; 15:1410634.

PMID: 38911860 PMC: 11190294. DOI: 10.3389/fimmu.2024.1410634.


Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis.

Martinez-Martinez L, Lacruz A, Querol L, Cortes-Vicente E, Pascual E, Rojas-Garcia R J Neurol. 2024; 271(7):4119-4130.

PMID: 38578496 DOI: 10.1007/s00415-024-12317-0.


Antiganglioside antibody frequency in routine clinical care settings.

Giesche N, Bohm-Gonzalez S, Kleiser B, Kowarik M, Dubois E, Stransky E Eur J Neurol. 2024; 31(7):e16290.

PMID: 38556758 PMC: 11236029. DOI: 10.1111/ene.16290.


References
1.
Emilien D, Hugh W . Diagnostic Utility of Auto Antibodies in Inflammatory Nerve Disorders. J Neuromuscul Dis. 2016; 2(2):107-112. PMC: 5271420. DOI: 10.3233/JND-150078. View

2.
Kuwabara S, Nakata M, Sung J, Mori M, Kato N, Hattori T . Hyperreflexia in axonal Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis. J Neurol Sci. 2002; 199(1-2):89-92. DOI: 10.1016/s0022-510x(02)00088-6. View

3.
Alaedini A, Latov N . Detection of anti-GM1 ganglioside antibodies in patients with neuropathy by a novel latex agglutination assay. J Immunoassay. 2000; 21(4):377-86. DOI: 10.1080/01971520009349543. View

4.
Shahrizaila N, Yuki N . Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry. 2012; 84(5):576-83. DOI: 10.1136/jnnp-2012-302824. View

5.
Kaida K, Ariga T, Yu R . Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review. Glycobiology. 2009; 19(7):676-92. PMC: 2688390. DOI: 10.1093/glycob/cwp027. View